Author

GS Nowakowski

Observed names: G. N. Nowakowski, G. Nowakowski

Institution: Mayo Clinic

Observed institution: Mayo Clinic

OpenAlex ID: A5088041725

Induction R2 Followed by Maintenance in Patients With Relapsed/refractory Mantle Cell Lymphoma: Interim Analysis From the Phase 3b Magnify Study

2021 · JP Sharman, JM Melear, et al. · Hematology Transfusion and Cell Therapy · 1

CO67 Tafasitamab Plus Lenalidomide (TAFA+LEN) Versus Pola-BR, R2, and CAR-T in Non-Transplant Eligible (NTE) Relapsed/Refractory (R/R) DLBCL: A Post Hoc Analysis of the RE-MIND2 Study Comparing Multiple Cohort-Balancing Approaches

2022 · R Córdoba, PL Zinzani, et al. · Value in Health

Do Cell‐of‐origin, Double Expresser, and Double Hit Status Affect Outcomes in Relapsed/refractory Diffuse Large B Cell Lymphoma (r/r Dlbcl)? a Prospective Observational Study

2021 · S. H. Desai, R. Mwangi, et al. · Hematological Oncology

Ps1262 Post Hoc Analysis of the Augment Phase Iii Randomized Study of Lenalidomide Plus Rituximab (r2) Vs Rituximab/placebo in Patients With Relapsed/refractory Marginal Zone Lymphoma

2019 · C. Thieblemont, J.P. Leonard, et al. · HemaSphere

Works count: 4

Citation count: 1

H-index: 1

I10-index: